This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D81.3 | Synonyms: ADA deficiency, ADA-SCID, adenosine deaminase deficiency
In 1972, Eloise Giblett and colleagues reported a complete absence of adenosine deaminase (ADA) activity in the red blood cells of two SCID patients, first identifying ADA deficiency as a cause of SCID. This was the first discovery linking immunodeficiency to a metabolic enzyme deficiency and became a revolutionary milestone in the convergence of immunology and biochemistry.
The ADA gene (20q13.11) was cloned in 1983, and the mechanism by which dATP and toxic metabolites selectively damage lymphocytes was subsequently elucidated. It was established that lymphocytes are particularly dependent on ADA activity compared with other cells.
ADA-SCID gene therapy performed in 1990 on Ashanthi DeSilva and Cynthia Cutshall is the world's first successful clinical case of gene therapy applied to humans. Later, in 2002, Aiuti's team in Italy achieved more definitive success with hematopoietic stem cell-based gene therapy.
In 1987, PEG (polyethylene glycol)-conjugated bovine ADA (PEG-ADA) was developed as an enzyme replacement therapy and began to be used for partial immune recovery in ADA-SCID patients.
In Korea, ADA-deficient SCID is reported extremely rarely. The gene therapy product Strimvelis (EMA approval 2016) and hematopoietic stem cell transplantation are the current standard treatments, and there have been diagnosed cases at some tertiary institutions in Korea.
The cause is biallelic loss-of-function mutations in the ADA gene (20q13.11), which encodes the ADA (Adenosine deaminase) enzyme. More than 70 pathogenic variants have been reported to date, of various types including nonsense mutations, missense variants, splice-site variants, and deletions.
ADA is an enzyme that deaminates adenosine to inosine and deoxyadenosine to deoxyinosine. In ADA deficiency, adenosine and deoxyadenosine accumulate, and the toxic metabolite dATP accumulates at particularly high concentrations in lymphocytes. This selectively destroys lymphocytes through inhibition of ribonucleotide reductase and induction of apoptosis.
ADA deficiency follows autosomal recessive inheritance. The ADA gene is located on the long arm of chromosome 20 (20q13.11); heterozygous carriers have ADA enzyme activity reduced to about 50% but have no clinical symptoms.
Complete loss-of-function (null) variants cause severe SCID with onset in the neonatal period or infancy. Partial loss-of-function variants show a varied spectrum, including ① late-onset ADA deficiency: gradual immune decline in childhood or adulthood, and ② the adult-onset form: only mild immune decline.
ADA deficiency accounts for about 10~15% of all SCID and is the most common type of autosomal recessive SCID. The worldwide incidence is estimated at about 1/200,000~1/1,000,000 newborns, and carrier frequency and incidence are higher in populations with a high frequency of consanguineous marriage.
It is distributed worldwide and is not limited to particular ethnic groups or regions. Specific founder mutations have been reported in some populations (e.g., some African populations).
There are very few patients with ADA deficiency in Korea, and accurate prevalence statistics are not known. There are cases registered under D81.3 with the Korea Disease Control and Prevention Agency (KDCA) Rare Disease Information Center, and domestic cases treated with HSCT have also been reported.
In ADA deficiency, adenosine and deoxyadenosine accumulate in excess. Deoxyadenosine is phosphorylated by deoxyadenosine kinase to dAMP → dADP → dATP, greatly expanding the intracellular dATP pool. Lymphocytes have high deoxyadenosine kinase activity and low 5'-nucleotidase activity, making them particularly vulnerable to dATP toxicity.
Excessive dATP accumulation inhibits ribonucleotide reductase, blocking DNA synthesis, and induces apoptosis through p53-dependent and mitochondrial pathways. In addition, inhibition of S-adenosylhomocysteine hydrolase (SAHase) impairs methylation reactions, so that the development and function of NK cells and T and B cells are all impaired.
Beyond the lymphoid system, the toxic metabolites of ADA deficiency affect skeletal development, and costochondral junction abnormalities may occur. Neurodevelopmental delay, hearing impairment, and behavioral disorders have also been reported in some patients.
Severe recurrent infections occur within a few weeks to months after birth. Pneumonia (PCP, CMV, adenovirus pneumonia), chronic diarrhea, oral candidiasis, sepsis, and skin infections are frequent. Failure to thrive and poor weight gain are prominent.
Cup-shaped widening and flaring of the costochondral junctions, pelvic abnormalities, and spinal deformities may be found on radiographic examination. These are important clues for differentiation from other types of SCID.
Intellectual impairment, developmental delay, hearing loss, and behavioral abnormalities are reported in some patients. Neurodevelopmental abnormalities may not fully improve even after ADA replacement therapy or gene therapy.
In patients with partial loss-of-function variants, gradual T-cell decline, recurrent respiratory infections, autoimmune phenomena, and lung function abnormalities appear in childhood or adulthood.
Failure to thrive, absent thymic shadow (chest radiograph), underdeveloped tonsils and lymph nodes. On radiographic examination, costochondral junction abnormalities (cuppage flaring) and pelvic dysplasia findings are relatively specific to ADA deficiency.
Flow cytometry shows marked reduction of T (CD3+), B (CD19+), and NK (CD16+/CD56+) cells - T-B-NK- phenotype. Overall reduction of serum immunoglobulins. Absent T-cell proliferative responses.
ADA enzyme activity measurement in red blood cells (less than 1% of normal), markedly elevated dATP concentration in plasma/red blood cells, and reduced S-adenosylhomocysteine hydrolase (SAHase) activity are diagnostic findings.
TREC is extremely low or undetectable, giving a positive result on newborn screening. After confirming the T-B-NK- phenotype, ADA deficiency can be confirmed with an ADA enzyme activity assay.
In some regions/countries, ADA enzyme activity is measured in dried blood spots as an additional item in newborn screening. This is a method of directly screening for ADA deficiency.
If there is an affected sibling, immediate genetic testing and enzyme activity measurement are needed.
Quantitative measurement of ADA enzyme activity in red blood cells is the primary diagnostic method. In patients with ADA deficiency, ADA activity is less than 1% of normal, and in carriers it is about 50%.
Biallelic pathogenic variants are confirmed by sequencing of the ADA gene (20q13.11). In patients receiving PEG-ADA treatment, red blood cell ADA activity may be elevated by exogenous ADA, so genetic testing is more important for diagnosis.
Measurement of plasma/red blood cell dATP and adenosine concentrations is useful for monitoring disease activity and treatment response.
Prenatal diagnosis is possible by ADA enzyme activity or genetic analysis of fetal cells obtained by CVS or amniocentesis.
HSCT from an HLA-matched sibling donor is the first-line treatment. If successful, ADA deficiency can be cured. When no matched donor is available, an unrelated donor or haploidentical transplantation is considered.
PEG-conjugated bovine ADA (Elapegademase, Revcovi) is given by intramuscular injection 1~2 times per week to supplement plasma ADA activity. It lowers toxic metabolite levels and induces partial immune recovery, but immune recovery is incomplete compared with HSCT or gene therapy. It is also used as bridging therapy before HSCT or gene therapy.
Strimvelis (orcasemigene vec) is a retrovirus-based gene therapy product in which the ADA gene is inserted into autologous CD34+ hematopoietic stem cells, and it was approved by the European Medicines Agency (EMA) in 2016. It is a strong treatment option when no HLA-matched donor is available, and long-term follow-up studies have confirmed its immune reconstitution effect.
IVIG administration, PCP prophylaxis, avoidance of live vaccines, protective isolation. PEG-ADA treatment has the advantage that it can be given without immunosuppressants or cytotoxic conditioning.
Long-term survival after HLA-matched sibling HSCT reaches 80~90%. Outcomes with unrelated donors or haploidentical transplantation are relatively lower but have been improving recently.
In Strimvelis clinical trials, survival at 5 years or more was over 90%, and most patients achieved immune reconstitution without IVIG dependence.
PEG-ADA reduces toxic metabolites and induces partial immune recovery, but long-term treatment has limitations such as formation of anti-PEG-ADA antibodies, resistance, and incomplete immune recovery.
In some patients, neurodevelopmental abnormalities may persist even after treatment, and long-term follow-up is needed.
TREC-based newborn screening allows early diagnosis within a few days after birth. Some countries include ADA enzyme activity in newborn screening for more direct screening.
Because inheritance is autosomal recessive, parents of an affected child are advised to receive carrier counseling and prenatal genetic diagnosis (CVS/amniocentesis) in subsequent pregnancies.
After diagnosis and until treatment begins, live vaccines are avoided, and PCP prophylaxis, IVIG, and protective isolation are provided. Live vaccines such as BCG are absolutely contraindicated.